A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
Urinary Incontinence
About this trial
This is an interventional treatment trial for Urinary Incontinence focused on measuring nocturia, urinary incontinence, overactive bladder, tolterodine, sleep, sleep disorder, menopause, midlife women, psychological tests
Eligibility Criteria
Inclusion Criteria: Post-menopausal women, age 45 to 65 years old. No menses for at least 6 months before the study start. Have at least 14 episodes of nocturia per week. Have at least 4 hot flashes daily. Overall good health, as evidenced by a letter from the primary care provider. Agree not to use exogenous hormones including soy isoflavones or soybean-based shakes, or nutritional supplements that potentially reduce hot flashes. Have discontinued all hormone treatments, systemic, topical, or vaginal, at least 60 days before admission and throughout participation in the study. Exclusion Criteria: Use of anti-cholinergic, hypnotic or sedating drugs Presence of urinary retention, gastric retention, chronic severe constipation,or narrow-angled glaucoma. A urinary tract infection within a month of study start. Undiagnosed abnormal vaginal bleeding. Benign or malignant liver disease. History or presence of chronic alcoholism or medication addiction within the past 5 yrs. An acute systemic infection within seven days before the study start. Concurrent participation in another clinical trial and/or receiving an experimental medication/device in the last 30 days before admission to the study. History of shift work within the past 6 months. -
Sites / Locations
- Massachusetts General Hospital
- Brigham & Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Tolterodine
Placebo
Tolterodine 4 mg q.d. X 8 weeks
A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine